- Linda L. Wong, MD
Professor, Department of Surgery, University of Hawaii, Honolulu, HI, USA.
Associate Chairman, John A. Burns School of Medicine, University of Hawaii;
Associate Member, Cancer Biology, University of Hawaiʻi Cancer Center;
Director, Liver Transplant Program, the Queen's Medical Center.
Website | E-mail
- Ghassan Abou-Alfa, MD, MBA
Professor, Memorial Sloan Kettering Cancer Center, Weill Medical College at Cornell University, New York, NY, USA.
Ex-chair, NCI Hepatobiliary Task Force;
President, International Society of Gastrointestinal Oncology.
Website | E-mail
Special Issue Introduction
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer death globally. It has a high case fatality rate, and most cases are found at an advanced stage. What is more difficult in terms of detection and treatment is that there is much heterogeneity amongst the patients with HCC. Much of this is related to the underlying chronic liver disease that predisposes a patient to HCC. This differs by geography, genetic predispositions, infectious exposures, as well as diet and exercise. What one region finds important for diagnosis, treatment, and control of HCC may not be as relevant to other populations. However, it is essential that all clinicians and researchers involved in HCC be familiar with these differences in various populations as patients do migrate. These patients may retain the genetic predispositions but may have changed exposures to a new environment.
Hopefully, understanding differences in various populations will allow us to one day develop unifying theories on hepatocarcinogenesis and better strategies for early detection and prevention.
We invite original article, review, case report, perspectives, opinions and commentary, etc., to this project.
1. Kunisshery Mallath Mohandas Department of Clinical Hematology, Tata Medical Center, Kolkata, India.
2. Mohamed El-Kassas Helwan Universitydisabled, Cairo, Egypt.
The list is in no particular order and being updated.
Ethnicity, disparities, heaptocellualr carcinoma
Submission Deadline 1 Nov 2022